Intech Biopharm (6461) reported revenue of NT$4,000 for Oct 2026, -99.7% year on year and -99.9% from the previous month. Revenue for Jan–Oct 2026 was NT$49.5 million (-52.5% year on year).
In Oct 2026, it ranked No. 155 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$4,000 | -99.7% | -99.9% |
| Sep 2026 | NT$7.2 million | +18.1% | +27.5% |
| Aug 2026 | NT$5.7 million | +1,103.0% | +2,579.6% |
| Jul 2026 | NT$211,000 | -70.2% | -96.6% |
| Jun 2026 | NT$6.2 million | -91.3% | -13.4% |
| May 2026 | NT$7.1 million | -47.1% | +28.0% |
| Apr 2026 | NT$5.6 million | +43.7% | -35.5% |
| Mar 2026 | NT$8.6 million | +2,527.1% | +436.2% |
| Feb 2026 | NT$1.6 million | -72.4% | -78.3% |
| Jan 2026 | NT$7.4 million | +394.2% | +169.9% |
| Dec 2025 | NT$2.7 million | -56.7% | +413.9% |
| Nov 2025 | NT$533,000 | -84.1% | -65.7% |
| Oct 2025 | NT$1.6 million | +4.4% | -74.6% |
| Sep 2025 | NT$6.1 million | +22,496.3% | +1,198.1% |
| Aug 2025 | NT$470,000 | -91.2% | -33.7% |
| Jul 2025 | NT$709,000 | -78.3% | -99.0% |
| Jun 2025 | NT$70.5 million | +8,430.9% | +424.5% |
| May 2025 | NT$13.4 million | +679.7% | +247.4% |
| Apr 2025 | NT$3.9 million | +45.5% | +1,079.0% |
| Mar 2025 | NT$328,000 | -95.4% | -94.4% |
| Feb 2025 | NT$5.8 million | +246.9% | +289.8% |
| Jan 2025 | NT$1.5 million | -74.6% | -76.3% |
| Dec 2024 | NT$6.3 million | +2,056.7% | +88.9% |
| Nov 2024 | NT$3.3 million | -16.4% | +125.2% |
| Oct 2024 | NT$1.5 million | +29.2% | +5,403.7% |
Jan–Oct 2026 cumulative: NT$49.5 million (-52.5% YoY)
Other Biotech & Medical companies
Compare with peers: Intech Biopharm vs PEC / Intech Biopharm vs Lotus Pharm / Intech Biopharm vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
本月及本年較去年同期減少,主要因經銷商備貨減少以及去年認列海思科完成合約之技術服務收入6,804萬所致。
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16